Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Core Viewpoint - The market anticipates Arcutis Biotherapeutics, Inc. (ARQT) will report a year-over-year increase in earnings driven by higher revenues when it releases its results for the quarter ended June 2025 [1] Financial Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.18 per share, reflecting a year-over-year change of +57.1% [3] - Revenues are projected to be $72.57 million, representing a significant increase of 135.2% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 17.02% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10] - Arcutis Biotherapeutics currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12][13] Historical Performance - In the last reported quarter, Arcutis Biotherapeutics was expected to post a loss of $0.21 per share but delivered a loss of -$0.20, resulting in a surprise of +4.76% [14] - The company has beaten consensus EPS estimates in each of the last four quarters [15] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Halozyme Therapeutics (HALO) is expected to report earnings of $1.23 per share for the same quarter, indicating a year-over-year change of +35.2% [19] - Halozyme's revenue is projected to be $286.12 million, up 23.7% from the previous year, with a revised consensus EPS estimate reflecting a 1.5% increase [20]